Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ALUR NASDAQ:ICCM NASDAQ:IVF NASDAQ:NXL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$0.87-1.0%$0.79$0.23▼$3.33$13.06M-0.131.56 million shs26,379 shsICCMIceCure Medical$4.36-16.5%$8.24$3.75▼$42.00$12.25M0.461,547 shs77,179 shsIVFINVO Fertility$1.59-4.2%$1.95$1.38▼$183.60$2.84M2.33781,193 shs145,729 shsNXLNexalin Technology$0.52-3.0%$0.41$0.31▼$2.00$10.78M3.81.38 million shs503,191 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies-0.99%+22.65%+28.06%+27.81%-69.76%ICCMIceCure Medical-16.48%-33.64%-45.36%-76.93%-85.89%IVFINVO Fertility-4.22%-15.43%-12.15%-62.54%-99.16%NXLNexalin Technology-3.00%-14.15%+50.49%+18.73%-57.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$0.87-1.0%$0.79$0.23▼$3.33$13.06M-0.131.56 million shs26,379 shsICCMIceCure Medical$4.36-16.5%$8.24$3.75▼$42.00$12.25M0.461,547 shs77,179 shsIVFINVO Fertility$1.59-4.2%$1.95$1.38▼$183.60$2.84M2.33781,193 shs145,729 shsNXLNexalin Technology$0.52-3.0%$0.41$0.31▼$2.00$10.78M3.81.38 million shs503,191 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies-0.99%+22.65%+28.06%+27.81%-69.76%ICCMIceCure Medical-16.48%-33.64%-45.36%-76.93%-85.89%IVFINVO Fertility-4.22%-15.43%-12.15%-62.54%-99.16%NXLNexalin Technology-3.00%-14.15%+50.49%+18.73%-57.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies 2.00Hold$3.00244.51% UpsideICCMIceCure Medical 2.40Hold$62.701,338.07% UpsideIVFINVO Fertility 2.50Moderate Buy$20.001,157.86% UpsideNXLNexalin Technology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest IVF, NXL, ALUR, and ICCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026ICCMIceCure Medical Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$90.00 ➝ $30.005/6/2026IVFINVO Fertility Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/4/2026ICCMIceCure Medical Alliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/21/2026ICCMIceCure Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$17.21M0.76N/AN/A($30.08) per share-0.03ICCMIceCure Medical$3.57M3.43N/AN/A$3.72 per share1.17IVFINVO Fertility$6.84M0.42N/AN/A($3,583.22) per share0.00NXLNexalin Technology$275.58K39.11N/AN/A$0.20 per share2.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$7.20M-$2.03N/AN/AN/A-199.96%N/A-77.13%8/18/2026 (Estimated)ICCMIceCure Medical-$15.06M-$7.21N/AN/AN/A-441.60%-211.73%-119.13%8/12/2026 (Estimated)IVFINVO Fertility-$9.10M-$3,151.46N/AN/AN/A-417.02%N/A-92.42%N/ANXLNexalin Technology-$8.22M-$0.47N/AN/AN/A-3,018.12%-191.88%-166.43%N/ALatest IVF, NXL, ALUR, and ICCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2026Q4 2025IVFINVO FertilityN/A$472.78N/A$472.78N/A$1.60 million5/12/2026Q1 2026ICCMIceCure Medical-$0.90-$1.80-$0.90$0.06$1.34 million$0.91 million5/8/2026Q1 2026NXLNexalin Technology-$0.10-$0.11-$0.01-$0.11$0.02 million$0.01 million3/25/2026Q4 2025NXLNexalin Technology-$0.12-$0.13-$0.01-$0.13$0.08 million$0.17 million3/17/2026Q4 2025ICCMIceCure Medical-$1.20-$1.80-$0.60-$0.0620$1.30 million$1.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/AIVFINVO FertilityN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A1.260.94ICCMIceCure MedicalN/A2.521.97IVFINVO FertilityN/A0.120.10NXLNexalin TechnologyN/A4.073.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%ICCMIceCure Medical0.62%IVFINVO Fertility12.02%NXLNexalin Technology0.65%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies8.10%ICCMIceCure Medical2.44%IVFINVO Fertility0.72%NXLNexalin Technology25.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies50114.99 million11.28 millionNo DataICCMIceCure Medical602.81 million2.74 millionNot OptionableIVFINVO Fertility101.79 million1.77 millionNo DataNXLNexalin Technology320.58 million15.38 millionNot OptionableIVF, NXL, ALUR, and ICCM HeadlinesRecent News About These CompaniesNexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and InsomniaJune 4 at 10:00 AM | globenewswire.comNexalin Technology (NXL) Expected to Announce Quarterly Earnings on WednesdayMay 27, 2026 | americanbankingnews.comNexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research ...May 21, 2026 | markets.businessinsider.comNexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain InjuryMay 21, 2026 | globenewswire.comNexalin Technology, Inc.: Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal TrialMay 20, 2026 | finanznachrichten.deNexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal TrialMay 19, 2026 | globenewswire.comNexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic ...April 28, 2026 | finance.yahoo.comNexalin Technology (NXL) price target decreased by 50.00% to 2.04April 28, 2026 | msn.comNexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic InsomniaApril 28, 2026 | globenewswire.comMaxim Group Remains a Buy on Nexalin Technology, Inc. (NXL)April 23, 2026 | theglobeandmail.comNexalin Advances Pivotal Insomnia Trial for HALO ClarityApril 22, 2026 | tipranks.comNexalin Technology, Inc. to Advance Pivotal Clinical Trial for HALO™ Clarity Device Aimed at Treating Moderate-to-Severe InsomniaApril 22, 2026 | quiverquant.comQNexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 EnrollmentApril 22, 2026 | globenewswire.comNexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and ChinaApril 16, 2026 | finance.yahoo.comNexalin Technology, Inc.: Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and ChinaApril 16, 2026 | finanznachrichten.deNexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and ChinaApril 15, 2026 | globenewswire.comJoin Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21April 15, 2026 | finance.yahoo.comJoin Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21April 14, 2026 | globenewswire.comNexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female AdolescentsApril 10, 2026 | markets.businessinsider.comNexalin Technology, Inc. Reports Significant Reductions in Self-Injury Behaviors and Depressive Symptoms in BMC Psychiatry Publication on DIFS ApproachApril 9, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIVF, NXL, ALUR, and ICCM Company DescriptionsAllurion Technologies NYSE:ALUR$0.87 -0.01 (-0.99%) As of 06/5/2026 03:58 PM EasternAllurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.IceCure Medical NASDAQ:ICCM$4.36 -0.86 (-16.48%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$4.28 -0.09 (-1.95%) As of 06/5/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.INVO Fertility NASDAQ:IVF$1.59 -0.07 (-4.22%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.50 -0.09 (-5.35%) As of 06/5/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.Nexalin Technology NASDAQ:NXL$0.52 -0.02 (-3.00%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.52 +0.00 (+0.25%) As of 06/5/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
